Akebia Q2 2022 Earnings Report
Key Takeaways
Akebia Therapeutics reported a net income of $29.3 million for Q2 2022, a significant turnaround from the $83.0 million net loss in Q2 2021. The company saw a 32.4% increase in net Auryxia product revenue, reaching $43.7 million. Additionally, Akebia regained full rights to vadadustat in the U.S., Europe, and other markets and increased its 2022 net Auryxia product revenue guidance to $170 - $175M.
Net Auryxia product revenue increased by 32.4% to $43.7M compared to Q2 2021.
2022 net Auryxia product revenue guidance was increased to $170 - $175M.
Akebia regained full rights to vadadustat in the U.S., Europe, and other markets.
Operating expenses were decreased to support the company's three strategic pillars.
Akebia
Akebia
Akebia Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income